Rozanolixizumab (Rystiggo) (AChR-positive and MuSKR-positive gMG)

Company: UCB

Clinical trial(s): MycarinG (Stage 3 complete) More Information

NICE status: Negative draft guidance published after first committee meeting, second and third committee meetings have now taken place (Q4 2025), and we are awaiting the outcome of these.

MHRA status: Approved

Learn more about rozanolixizumab.